Published by Global Banking & Finance Review®
Posted on August 20, 2025
1 min readLast updated: January 22, 2026
Aurobindo Pharma is leading the race to acquire Zentiva for $5.5 billion, potentially marking the largest acquisition by an Indian pharma firm.
(Reuters) -India's Aurobindo Pharma is leading the race to buy Prague-based drugmaker Zentiva for up to $5.5 billion, the Economic Times reported on Wednesday, in what could be the largest-ever acquisition by an Indian pharmaceutical firm.
Aurobindo is in talks with Zentiva's owner U.S.-based private equity firm Advent International, the report said, citing people aware of the matter.
However, Aurobindo, in a statement to exchanges, said no binding agreements have been signed by the company's board.
The company's shares slid as much as 4.7% in early trade after the report, before trimming it to 3.7% lower.
Advent International and Zentiva declined to comment on the report.
(Reporting by Kashish Tandon in Bengaluru; Editing by Harikrishnan Nair)
The reported acquisition price for Zentiva is up to $5.5 billion.
Zentiva is currently owned by U.S.-based private equity firm Advent International.
Aurobindo's shares slid as much as 4.7% in early trade following the report, before recovering slightly to a 3.7% decline.
Aurobindo stated that no binding agreements have been signed by the company's board.
Both Advent International and Zentiva declined to comment on the report.
Explore more articles in the Finance category
